Aidan O'Brien has confirmed dual Group One-winning filly Magical will be aimed at the QIPCO Irish Champions Stakes, the feature race on day one of the Longines Irish Champions Weekend next month.
Six Group One races will go off at Leopardstown and the Curragh over the weekend of 14/15 September.
Speaking at Ballydoyle this morning, where he galloped a number of his stable stars, O'Brien said: "Magical has had a break since her last run and the plan is for her to go to the QIPCO Irish Champion Stakes at Leopardstown with or without a run. We also have Circus Maximus, Japan, Anthony Van Dyck and Sir Dragonet as possible runners.
"For the Coolmore Stud Fastnet Rock Matron Stakes, we are looking at Hermosa and Just Wonderful while Mount Everest could be one for the Kilternan Stakes.
"Lancaster House will go for the Clipper Logistics Boomerang Stakes and Never No More is also a possible there. Lope Y Fernandez and Toronto are two possible runners in the KPMG Champions Juvenile Stakes.
"At the Curragh on day two, we are looking at maybe running Armory, Arizona and Royal Lytham in the Goffs Vincent O'Brien National Stakes while Love could go for the Moyglare Stud Stakes.
"Both Capri and Kew Gardens are potential runners in the Comer Group International Irish St Leger while in the Group 1 Derrinstown Stud Flying Five Stakes we have Ten Sovereigns and Fairyland as possibles. We are looking at the Moyglare "Jewels" Blandford Stakes for Pink Dogwood and Fleeting."
An addition to this year's event is The Pat Smullen Champions Race for Cancer Trials Ireland on the second day of Longines Irish Champions Weekend at the Curragh.
Legendary jockeys, including AP McCoy, Ruby Walsh, Kieren Fallon, Johnny Murtagh, Richard Hughes, Charlie Swan and Joseph O'Brien, have been assembled by Smullen for the race at the Curragh.
All monies raised for The Pat Smullen Champions Race for Cancer Trials Ireland and other various fund-raising activities over Longines Irish Champions weekend will be donated to Cancer Trials Ireland for their work into pancreatic cancer trials and research.